IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| Applica | nts: Rodger, et al. | | |
|---------|--|----------------------|--|
| | No. To be assigned COMBINATION THERAPY FOR TREATING CHRONIC NFLAMMATORY DISEASES | Art Unit: _Examiner: | |

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

| 7 | | THE COLUMN | |
|-----------------|-----------------|---------------------|----|
| DATE OF DEPOSIT | 12 21 2 | 005 | |
| DATE OF DEPOSIT | 000 | 6047870 | र |
| | | | - |
| I HEREBY CENT | DEED WELL AND | CONTENTONDENCE IS | |
| BEING DEPOSIT | ED WITH THE U | MIED STATES POSTAL | |
| | | TOST OFFICE TO | |
| ADDRESSEE" 8 | EFORE S P.M. OF | N THE ABOVE DATE IN | |
| | | SISTANT COMMISSION | ER |
| | | DM, D.C., 20231. | |
| , | mai Sc | hange | |

12121105

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 28313-1450, on the date appearing below.

MERCK & CO., INC.

By_____ Date ____

RELATED APPLICATION

INFORMATION DISCLOSURE STATEMENT POTITIO 21 DEC 2005

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

| U. S. SERIAL NUMBER | FILING DATE | MERCK CASE |
|---|--|---------------------------|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| If this is inconvenient, additional copies will be submitted upon request | · | |
| 6. In accordance with 37 C.F.R. 1.97, (check one) | | |
| the attached information is filed within three months of the filing date | te of the captioned case. | |
| the attached information is filed more than three months after the filed Office Action on the merits. | ling date but prior to the m | ailing of a first |
| the attached information is filed before the mailing of a first Office a examination under §1.114. | action after the filing of a re | quest for continued |
| Office Action on the merits, but before the mailing date of a Final A otherwise closes prosecution in the application. The enclosed auth Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p). | ction, Notice of Allowance, norization is therefore giver | or an action that |
| each item of information contained in this Information Disclosure S from a foreign patent office in a counterpart foreign application not Statement. | | • |
| each item of information contained in the information disclosure statement from a foreign patent office in a counterpart application and this condesignated in §1.56(c) more than thirty days prior to the filing of the | mmunication was not rece | ived by any individual |
| no item of information contained in this Information Disclosure States foreign patent office in a counterpart foreign application, and, to the after making reasonable inquiry, was known to any individual designmenths prior to the filing of this Statement. | e knowledge of the person | signing the certification |
| | | |

Respectfully submitted,

By: Raynard Yuro

Attorney For Applicant(s)

Reg. No. 45 570

Reg. No. <u>45,570</u>
MERCK & CO., INC.

Patent Dept., RY60-30 P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-<u>0182</u>

Date: December 19, 2005

Approved for use through 161/2006 ONB 0651-0031

Approved for use through 161/2006 ONB 0651-0031

Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

| | Substitute for form 1449A/PT(| O . | | | COMPLETE IF KNOWN |
|------|--|-----------|-------------|------------------------|------------------------------|
| | INFORMATIO | N DIS | CLOSURE | Application Number | To be assigned R R R R R R R |
| | INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | DI ICANIT | Filing Date | | |
| | STATEMENT | BY AP | PLICANI | First Named Inventor | Rodger, et al. |
| | | * | | Group Art Unit | |
| | (use as many sh | eets as n | ecessary) | Examiner Name | |
| Shee | t 1 | of | 2 | Attorney Docket Number | 21411P |

| | | U.S. Patent Document | | | Date of Publication of |
|-----------------------|-------------|----------------------|----------------------------|---|---------------------------|
| Examiner Initials* | Cite No. | Number | Kind Code (if known) | Name of Patentee or Applicant of Cited Document | Cited Document MM-DD-YYYY |
| | | 2003/0157061 | | Dennis A. Bennett | 08/21/2003 |
| | | 2003/0077297 | | Chen, et al. | 04/24/2003 |
| | | | | | |
| | · | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | 11/1/2 | | |
| | | | | | |
| | | | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-------------|----------------------|----------------------------|---|------------------------------|--|--|
| Evo-sis or | 0:4 | Foreign Patent Docum | | | Date of Publication of | | |
| Examiner Initials* | Cite No. | Office Number | Kind Code (if known) | Name of Patentee or Applicant of Cited Document | Cited Document MM-DD-YYYY | | |
| | | WO 03/016248 | | BRISTOL-MYERS SQUIBB COMPANY | 02/27/2003 . | | |
| | | WO 03/002713 | | ABGENIX, INC. | 01/09/2003 | | |
| | | WO 01/37808 | | LIPOCINE, INC. | 05/31/2001 | | |
| | | WO 01/28555 | | LIPOCINE, INC. | 04/26/2001 | | |
| | | WO 01/00229 | | PHARMACIA CORPORATION | 01/04/2001 | | |
| | | EP 1 104 760 B1 | | PFIZER PRODUCTS INC. | 03/12/2003 | | |
| | V | EP 1 104 760 A1 | | PFIZER PRODUCTS INC. | 06/06/2001 | | |
| | | WO 2005/004806 | | MERCK & CO. INC. | 01/20/2005 | | |
| | | | | | | | |
| | | | | | | | |

| Examiner Signature | Date Considered | |
|-----------------------|---|--|
| | استان میں اور | |

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

| Su | bubstitute for form 1449B/PTO | | | | COMPLETE IF KNOWN |
|-------|-------------------------------|------|-----------|------------------------|---------------------|
| | NFORMATION | DIS | CLOSURE | Application Number | To be seemed 5616/C |
| | TATEMENT BY | A D | DI ICANT | Filing Date | |
| | TATE VIEW DX | Ar | PLICANI | First Named Inventor | Rodger, et al. |
| | / | | 3 | Group Art Unit | |
| | (use as many sheets | as n | ecessary) | Examiner Name | |
| Sheet | 2 | of | 2 | Attorney Docket Number | 21411P |

| | | NON PATENT LITERATURE DOCUMENTS |
|--------------------|-------------|---|
| Examiner Initials* | Cite No. | Include name of the author, title, date, page(s), volume-issue number(s) and place of publication. |
| | | El Desoky, et al., Database Biosis On Stn. Accession No. 2001:182368, Current Therapeutic Research, Vol., 61, No. 2, pp. 92-112, 2001 |
| | | Saravanan, et al., Expert Opinion, "Advances in the Treatment of Rheumatoid Arthritis: Old Versus New Therapies", Vol. 3 No. 7, pp 845-856, 2002 |
| | | Hocherl, et al., Journal of American Society of Nephrology, "Cyclosporine A Suppresses Cyclooxygenase-2 Expression in the Rat Kidney", Vol. 13, No. 10, pp. 2427-2436, 2002 |
| | | Nurmohamed, et al, Drugs, "Cardiovascular Risk Profile of Antirheumatic Agents in Patients with Osteoarthritis and Rheumatoid Arthritis", Vol. 62, No. 11, pp. 1599-1609, 2002 |
| | | Luong, et al, The Annals of Pharmacotherapy, "Treatment Options for Rheumatoid Arthritis: Celecoxib, Leflunomide, Etanercept, and Infliximab", Vol. 34 No. 6, pp. 743-760, 2000 |
| | | Ehab S. El Desoky, MD, Current Therapeutic Research, "Pharmacotherapy of Rheumatoid Arthritis: An Overview", Vol. 62 No. 2, pp. 92-112, 2001 |
| | | |
| | | |
| | | |
| | | |
| · | | |
| | | |
| | | |
| | | |
| | | |

| Examiner | Date | |
|-----------|------------|--|
| Signature | Considered | |

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.